Siemens Introduces INNOVANCE Heparin Assay

- Truly ready-to-use liquid heparin testing for both unfractionated (UF) and low molecular weight (LMW) heparin
- Eliminates the risk of evaluating on the wrong calibration curve by employing a single curve for both UF and LMW heparin
- Available for BCS® XP System and the Sysmex® CS-2000i, CS-2100i & CS-5100 Systems

Siemens Healthcare is announcing the availability of the new INNOVANCE® Heparin Assay for the BCS XP System and the Sysmex CS-2000i, CS-2100i and the CS-5100 Systems. This truly liquid testing solution generates precise results with fewer steps, streamlining workflow with easy-to-use reagents and a single hybrid calibration curve for both unfractionated heparin (UFH) and low molecular weight heparin (LMWH).

Non-liquid heparin assays typically require labor-intensive reconstitution and mixing of reagents before testing can occur, impacting laboratory workflow. Unlike other liquid heparin assays that may need to stand for up to 30 minutes before use, the INNOVANCE Heparin Assay can be used immediately. The assay’s single calibration curve for both UFH and LMWH adds confidence to results by eliminating the risk of evaluation on the wrong curve.
"Current methods are complex and time consuming, potentially leading to a delay in patient care," said Franz Walt, President of Siemens Healthcare Laboratory Diagnostics business area. "Our new assay is designed to significantly reduce hands-on time and improve security so that heparin testing can become a more routine laboratory operation."

Heparin is an anticoagulant used to prevent and treat blood clots in at-risk patients. It exists in two forms, UFH and LMWH, both of which are widely used as prophylactic and therapeutic anticoagulants.

The INNOVANCE Heparin Assay utilizes a universal calibrator set that is traceable to the World Health Organization (WHO) standards for UFH and LMWH. Dedicated controls for UFH and LMWH have two levels each, and the hybrid calibration curve includes five levels for greater precision and accuracy. It exhibits excellent correlation between Siemens and Sysmex systems and offers a comparable number of tests per kit across all systems.

1. Sysmex is a registered trademark of the Sysmex Corporation
2. Not all product offerings are available in all countries. Product availability may vary from country to country and is subject to varying regulatory requirements

This press release and press pictures are available at www.siemens.com/press/PR2015100034HCEN

Contact for journalists:
Siemens Healthcare, Media and Public Relations
John Gillespie, phone: +1 914-524-2636
E-mail: john.gillespie@siemens.com

Follow us on Twitter at: www.twitter.com/siemenshealth

Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world’s largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of combined cycle turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance
imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2014, which ended on September 30, 2014, Siemens generated revenue from continuing operations of €71.9 billion and net income of €5.5 billion. At the end of September 2014, the company had around 343,000 employees worldwide on a continuing basis. Further information is available on the Internet at http://www.siemens.com.